Corphena Solution
FDA Label NDC 73684-300

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Blucrest Pharmaceuticals Llc for the product Corphena (NDC 73684-300). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding other, description, clinical pharmacology, indications and usage, contraindications, use in newborn or premature infants, use in nursing mothers, use in lower respiratory disease, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Drug Interaction

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

* Please review the disclaimer below.